Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Протокол NCT03410108
Описание
Статус выполнения
completedResults
Ход выполнения
100%
29.01.2018
28.07.2021
Цели
The purpose of this study is to evaluate efficacy and safety of brigatinib in Japanese participants with anaplastic lymphoma kinase (ALK)-positive NSCLC.
Организация, проводящая КИ
Takeda
Фаза КИ
II
Количество пациентов
104

Новости и обновления